Zacks Investment Research upgraded shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) from a sell rating to a hold rating in a report released on Tuesday morning.

According to Zacks, “Theravance’s second-quarter 2017 results are discouraging as it reported wider-than-expected loss with revenue missing estimates. We are positive on Theravance’s efforts to expand the Vibativ’s label, which, if approved for additional indications, would be commercially significant. Further, Theravance’s collaboration agreement with Mylan for revefenacin, is a big positive. Though the company’s sole marketed product, Vibativ, continues to perform well, Theravance’s dependence on Vibativ for growth is concerning. Nevertheless, its pipeline programs targeting the therapeutic areas are highly competitive which could affect the company’s operating results. Also, any agreement termination might be a huge setback for the company, as had been the case in the past. Its shares have underperformed the industry so far this year.”

A number of other research analysts also recently commented on the company. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the company a buy rating in a research report on Wednesday, July 19th. ValuEngine upgraded Theravance Biopharma from a sell rating to a hold rating in a research report on Friday, June 2nd. BidaskClub upgraded Theravance Biopharma from a hold rating to a buy rating in a research report on Saturday, June 24th. Needham & Company LLC reiterated a buy rating on shares of Theravance Biopharma in a research report on Wednesday, August 2nd. Finally, Leerink Swann set a $47.00 target price on Theravance Biopharma and gave the company a buy rating in a research report on Wednesday, May 10th. Four analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $41.63.

Shares of Theravance Biopharma (TBPH) opened at 31.43 on Tuesday. Theravance Biopharma has a one year low of $23.15 and a one year high of $43.44. The stock has a 50 day moving average of $30.03 and a 200-day moving average of $35.19. The company’s market capitalization is $1.69 billion.

COPYRIGHT VIOLATION NOTICE: “Theravance Biopharma, Inc. (TBPH) Stock Rating Upgraded by Zacks Investment Research” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/09/theravance-biopharma-inc-tbph-stock-rating-upgraded-by-zacks-investment-research.html.

In related news, SVP Frank Pasqualone purchased 4,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average cost of $26.34 per share, for a total transaction of $105,360.00. Following the completion of the transaction, the senior vice president now directly owns 213,180 shares in the company, valued at $5,615,161.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Bradford J. Shafer sold 14,670 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total value of $451,395.90. Following the completion of the sale, the executive vice president now owns 134,327 shares of the company’s stock, valued at $4,133,241.79. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 20,000 shares of company stock valued at $494,300. 6.10% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its position in Theravance Biopharma by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 230 shares during the last quarter. Susquehanna International Group LLP lifted its position in Theravance Biopharma by 56.8% in the second quarter. Susquehanna International Group LLP now owns 17,564 shares of the biopharmaceutical company’s stock worth $700,000 after buying an additional 6,364 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Theravance Biopharma by 3.9% in the second quarter. The Manufacturers Life Insurance Company now owns 31,221 shares of the biopharmaceutical company’s stock worth $1,244,000 after buying an additional 1,175 shares during the last quarter. State Street Corp lifted its position in Theravance Biopharma by 2.2% in the second quarter. State Street Corp now owns 889,682 shares of the biopharmaceutical company’s stock worth $35,443,000 after buying an additional 19,428 shares during the last quarter. Finally, QS Investors LLC bought a new stake in Theravance Biopharma in the second quarter worth $100,000. Institutional investors own 84.54% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.